Sign up to save your podcasts
Or
Share Hiperuricemia asintomática
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Hiperuricemia asintomática
La hiperuricemia asintomática es una condición muy común sobre la cual se derramado mucha tinta, específicamente con relación a su manejo. En este episodio discutiré cual es el impacto clínico de la hiperuricemia asintomática, tocaré brevemente su fisiopatología y contribuiré a confundirlos en cuanto a su tratamiento.
Estas son algunas de las referencias consultadas:
Bursill, D. et al. Gout, hyperuricemia, and crystal- associated disease network consensus statement regarding labels and definitions for disease elements in gout. Arthritis Care Res. 71, 427–434 (2019).
Richette, P. et al. 2016 updated EULAR evidence- based recommendations for the management of gout. Rheum. Dis. 76, 29–42 (2017).
Sivera, F. et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Rheum. Dis. 73, 328–335 (2014).
Dalbeth, N. et al. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Rev. Rheumatol. 13, 561–568 (2017).
Khanna, D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 64, 1431–1446 (2012).
Neogi, T. & Mikuls, T. R. To treat or not to treat (to target) in gout. Intern. Med. 166, 71–72 (2017).
Jensen, T. et al. Fructose and sugar: a major mediator of non-alcoholic fatty liver disease. Hepatol. 68, 1063–1075 (2018).
Johnson, R. J. et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation. J. Kidney Dis. 71, 851–865 (2018).
Yamanaka, H. Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids 30, 1018–1029 (2011).
View all episodes
By Daniel Xibille FriedmannLa hiperuricemia asintomática es una condición muy común sobre la cual se derramado mucha tinta, específicamente con relación a su manejo. En este episodio discutiré cual es el impacto clínico de la hiperuricemia asintomática, tocaré brevemente su fisiopatología y contribuiré a confundirlos en cuanto a su tratamiento.
Estas son algunas de las referencias consultadas:
Bursill, D. et al. Gout, hyperuricemia, and crystal- associated disease network consensus statement regarding labels and definitions for disease elements in gout. Arthritis Care Res. 71, 427–434 (2019).
Richette, P. et al. 2016 updated EULAR evidence- based recommendations for the management of gout. Rheum. Dis. 76, 29–42 (2017).
Sivera, F. et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Rheum. Dis. 73, 328–335 (2014).
Dalbeth, N. et al. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Rev. Rheumatol. 13, 561–568 (2017).
Khanna, D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 64, 1431–1446 (2012).
Neogi, T. & Mikuls, T. R. To treat or not to treat (to target) in gout. Intern. Med. 166, 71–72 (2017).
Jensen, T. et al. Fructose and sugar: a major mediator of non-alcoholic fatty liver disease. Hepatol. 68, 1063–1075 (2018).
Johnson, R. J. et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation. J. Kidney Dis. 71, 851–865 (2018).
Yamanaka, H. Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids 30, 1018–1029 (2011).